All In Biotech

Drug Trial Radar · NCT00158834

Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications

Comparison of Stepwise Treatment of Asthmatic Children With Salmeterol/Fluticasone Propionate Combination Product (Seretide®) and/or Fluticasone Propionate (Flixotide®) Based on PD20 Methacholine and Symptoms or Based on Symptoms Only (Children Asthma Therapy Optimal)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Nov 1999

Primary completion

Not stated

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate if, in children with asthma, a stepwise treatment (five levels varying from once daily fluticasone propionate 100mcg until twice daily a fixed combination of salmeterol and fluticasone propionate 50/500 mcg) based on symptom scores alone results in a sub-optimal treatment when compared to treatment based on cumulative symptom scores and bronchial hyperresponsiveness (PD20 methacholine).

Conditions

  • Asthma

Interventions

  • Salmeterol/Fluticasone propionate combination productDrug

  • Fluticasone propionateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Asthma symptom free days during the last 12 weeks of the treatment period.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Alkmaar, Netherlands

  • GSK Investigational Site

    Almere Stad, Netherlands

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Breda, Netherlands

  • GSK Investigational Site

    Eindhoven, Netherlands

  • GSK Investigational Site

    Groningen, Netherlands

  • GSK Investigational Site

    Hilversum, Netherlands

  • GSK Investigational Site

    Leiden, Netherlands

  • GSK Investigational Site

    Maastricht, Netherlands

  • GSK Investigational Site

    Rotterdam, Netherlands

  • GSK Investigational Site

    Sittard, Netherlands

  • GSK Investigational Site

    The Hague, Netherlands

  • GSK Investigational Site

    Utrecht, Netherlands

  • GSK Investigational Site

    Veldhoven, Netherlands

  • GSK Investigational Site

    Zwolle, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.